With an estimated 170 million chronically infected individuals, the hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. A protective vaccine does not exist to date and therapeutic options are still limited. At present, inferon-a (IFN-a) in combination with ribavirin is the treatment of choice for chronic hepatitis C. The mechanism of action of IFN-a is only partially understood and may involve both direct antiviral and immunomodulatory effects. Recently, the replicon system has allowed the investigation of the effect of IF-a and other cytokines on HCV RNA replication. In addition, data obtained in other experimental model systems indicate that HCV has evolved strategies to counteract the antiviral effect of IFN-a. Such mechanisms could contribute to the resistance to IFN-a therapy observed in many patients and may represent a general escape strategy of HCV contributing to viral persistence and pathogenesis. In the following, we will briefly review current concepts of the interaction between cytokines, primarily IFN-a, and HCV.
|Title of host publication||Cytokines in liver injury and repair|
|Subtitle of host publication||proceedings of Falk Symposium No. 125|
|Editors||A. M. Gressner, P. C. Heinrich, S. Matern|
|Place of Publication||The Netherlands|
|Publisher||Kluwer Academic Publishers|
|Number of pages||16|
|Publication status||Published - 2002|
|Event||Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125 - Hanover, Hanover, Germany|
Duration: 30 Sep 2001 → 1 Oct 2001
|Conference||Cytokines in liver injury and repair|
|Period||30/09/01 → 1/10/01|
Moradpour, D., FRESE, M., Heim, H., Haller, O., Bartenschlager, R., & Blum, H. E. (2002). Cytokines and hepatitis C virus replication. In A. M. Gressner, P. C. Heinrich, & S. Matern (Eds.), Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125 (pp. 105-120). The Netherlands: Kluwer Academic Publishers.